EICHOR
● Completed
A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema
Condition: Hereditary Angioedema · Sponsor: Ionis Pharmaceuticals, Inc.
About this study
The purpose of this study was to evaluate the clinical efficacy, safety, and tolerability of donidalorsen in participants with hereditary angioedema (HAE) type 1 (HAE-1), HAE type 2 (HAE-2), or HAE with normal C1-inhibitor (C1-INH) and to evaluate the effect of donidalorsen on plasma prekallikrein (PKK) and other relevant biomarkers.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (8)
| Medical Research of Arizona | Scottsdale, Arizona, United States | — |
| University of California San Diego (UCSD) | San Diego, California, United States | — |
| AIRE Medical of Los Angeles | Santa Monica, California, United States | — |
| Midwest Immunology Clinical | Plymouth, Minnesota, United States | — |
| Bernstein Clinical Research Center, LLC | Cincinnati, Ohio, United States | — |
| Penn State Hershey Medical Center | Hershey, Pennsylvania, United States | — |
| AARA Research Center | Dallas, Texas, United States | — |
| Amsterdam UMC, loc. AMC | Amsterdam, Netherlands | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04030598